Teva, Cobalt challenge Sepracor's patents for Lunesta

02/16/2009 | American City Business Journals

Sepracor announced in a regulatory filing that Teva Pharmaceuticals USA and Cobalt Laboratories requested FDA approval to produce a version of Sepracor's sleep drug Lunesta, which gained U.S. clearance in 2004. Sepracor said it intends to file a patent suit to delay the approval of the abbreviated new-drug applications.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX